Form 4: BrainStorm Cell Therapeutics CFO Equity Grant

Interim CFO Alla Patlis received an award of 100,000 restricted stock units from BrainStorm Cell Therapeutics.

Summary

• Alla Patlis, Interim Chief Financial Officer and Controller of BrainStorm Cell Therapeutics, was granted 100,000 restricted stock units (RSUs).
• The grant was issued on February 26, 2026.
• The RSUs vest in two equal tranches: 50% on the grant date and 50% on the six-month anniversary of the grant date, contingent upon continued employment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation with no material impact on the company's operational outlook.

Positives

• Equity-based compensation aligns the interests of the Interim CFO with those of shareholders.

Negatives

• The issuance of 100,000 shares results in minor dilution to existing shareholders.

Risks

• Continued reliance on equity compensation to retain key management personnel.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of an executive.

Industry Context

StockSavvy.ai notes that equity grants for interim executives are standard practice in the biotechnology sector to ensure leadership stability during transitional periods.

Comparison to Industry Standards

• The use of RSU vesting schedules is consistent with standard corporate governance practices for executive compensation in small-cap biotech firms.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the remaining 50% of the RSU award on August 26, 2026.

Key Dates

Keywords

BCLI, BrainStorm Cell Therapeutics, Insider Trading, Form 4, Equity Compensation, Biotech